![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
This is a retrospective analysis of women whose advanced breast cancer was treated with weekly low-dose doxorubicin (12 mg/m2) as second line therapy. The patients received doxorubicin as single agent therapy (group D, n=47) or combined with various cytotoxic (group D+CT, n=52) or with hormonal drugs (group D+ET, n=37). Objective responses were found in 23% in group D, in 33% in group D+CT and in 30% in group D+ET. Mean response duration was 11 months in group D+CT and group D+ET and 6 months in group D (p=0.007, Student's t-test). Median survival was 17 months in group D+CT and 9 months both in group D and group D+ET (p=0.01, Mantel-Cox). The toxicity was mild. However, nausea occurred more often in group D+CT than in group D (p=0.009, chi-square-test).